What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Several contract development and manufacturing organizations (CDMOs) have company-reported growth drivers in biologics, GLP-1-related services, integrated contracts and programs progressing toward commercial production. But those opportunities do not establish that CDMOs as a group—or any particular company—will outperform peers. Capacity has to be qualified, filled and used; customers can manufacture in-house; and demand does not guarantee attractive pricing or margins.
The company examples below show what to watch, not an independent sector forecast or stock ranking. Their targets cover different companies, periods and metrics, so they are not directly comparable.
What could drive CDMO growth?
A CDMO handles some part of a pharmaceutical or biotechnology company’s drug development and manufacturing. Providers differ substantially: one may focus on biologics or drug substance, another on sterile injectables, fill-finish or delivery systems. A rising market for a drug or modality therefore does not benefit every provider equally.
Biologics and specialized manufacturing
Biologics and other complex modalities can require specialized processes and capacity. In its May 8, 2026 business update, Lonza reported demand momentum across Integrated Biologics, Advanced Synthesis and Specialized Modalities, as well as multiple integrated contracts spanning drug substance and drug product. That is evidence of activity at Lonza, not a measure of demand across all CDMOs.
Free tools Windows power users keep installed
One-click scans. No signup required.
GLP-1 and obesity-related services
GLP-1-related manufacturing can involve drug substance, sterile fill-finish and delivery systems. OneSource Specialty Pharma said its drug-delivery capacity expansion was connected to GLP-1 commercialization, while Stevanato Group identified GLP-1 therapies among its focus areas. The opportunity depends on which step a supplier can perform and whether a customer selects and ramps that supplier.
Biosimilars, outsourcing and repeat business
OneSource described biosimilar programs and biologics supply-chain diversification as demand opportunities. It also reported that more than 70% of its new business wins came from existing customers in its Q3 FY26 presentation. Lonza reported integrated contract wins. Existing relationships and broader service contracts may offer a path to repeat work, but the value depends on contract terms, program progress, customer concentration and eventual commercial volumes.
What company outlooks actually say
These figures are management outlooks or targets, not realized results or a common forecast. Different fiscal periods and metric definitions make a direct ranking inappropriate.
| Company and source period | Reported outlook or target | Important qualification |
|---|---|---|
| Lonza, May 2026 business update | 2026 sales growth of 11–12% at constant exchange rates; core EBITDA margin above 32%. | Company outlook. Lonza expected a notably stronger first half than second half, citing the prior-year comparison, campaign timing, product releases and planned shutdowns; it also cited foreign-exchange headwinds. |
| OneSource Specialty Pharma, Q3 FY26 presentation | FY25–FY28 revenue CAGR target above 30%; steady-state EBITDA around 40%; targeted ROCE above 50% and net debt-to-EBITDA below 1.5x. | Company targets, not reported outcomes. The presentation showed FY28 revenue outlook of $400 million organically and more than $500 million in a scenario including a proposed acquisition; the acquisition case is conditional. |
OneSource also described a $75 million drug-delivery capacity investment and said it brought forward phase-two expansion. These are company-reported plans and investment details, not proof that the added capacity will produce revenue on schedule or earn the targeted returns.
Recommended Free Tools
A 2026 SEC-filed presentation associated with Laboratory Corporation of America Holdings describes a sterile-injectables CDMO growth plan and management goals of revenue CAGR above 12% and adjusted EBITDA margin above 25%. The available issuer metadata does not establish the presenting CDMO’s identity clearly enough to attribute those goals to a named peer here. Treat the figures as unverified for company-to-company comparison unless the filing identity and title are confirmed.
Why announced capacity is not the same as growth
A new line, expansion or customer contract is only one step toward recognized revenue. The practical sequence is commissioning, qualification, customer validation, commercial production, utilization and financial contribution. Delays or low utilization can leave a supplier carrying investment costs without the expected sales or margin benefit.
Stevanato’s validation and production milestones
In its Q2 2026 results presentation, Stevanato reported performance qualification of its first EZ-fill vial line and anticipated customer validations. It also described planned prefilled-syringe and cartridge capacity in EMEA and expected contract drug-delivery-system production to begin at the end of 2026. The validation and production dates are management plans as reported then, not confirmation that those milestones have since been completed.
Lonza’s large-scale capacity
Lonza said in May 2026 that interest in its Vacaville large-scale mammalian capacity remained high and discussed expected peak sales in the early 2030s. Interest and long-range peak-sales expectations are not the same as current utilization or near-term revenue. A reader assessing progress should look for qualification, contract conversion, production starts and reported financial contribution.
Why demand may not flow through to independent CDMOs
Pharmaceutical companies can manufacture internally
Novo Nordisk’s Q2 2026 presentation and H1 report describe internal capabilities across high-volume biologics, API manufacturing, filling, tableting and finishing, alongside planned investment in capacity and supply-chain flexibility. That makes the company’s reporting useful demand-side context, but it is not an independent CDMO forecast. Internal production can serve some demand that might otherwise go to a contractor.
Volume growth does not guarantee supplier economics
Novo Nordisk’s H1 report also discusses GLP-1 pricing and competition alongside demand and supply investment. That combination is a reminder that demand growth, realized prices and contract-manufacturer economics can move differently. For a CDMO, margins also depend on product mix, pricing, manufacturing efficiency, capital requirements and the pace at which capacity is utilized.
Timing can make results uneven
Lonza’s 2026 outlook illustrates how campaign schedules, product releases, shutdowns, prior-year comparisons and currency movements can affect reported growth and margins even when a company describes demand as sustained. The timing of a program or production campaign matters: a contract award should not be counted as immediate sales, and a planned expansion should not be treated as an operating asset that is already earning returns.
How to assess a CDMO’s growth prospects
Rather than treating “outperformance” as a settled prediction, compare each company with peers that have similar services and a defined reporting period. Useful checks include:
- Technology and service mix: Identify exposure to biologics, small molecules, sterile injectables, drug substance, drug product, fill-finish and delivery systems. A broad “CDMO” label can conceal very different capabilities.
- Demand conversion: Separate customer wins and development programs from validated capacity, commercial launches and recognized revenue. Check contract minimums, launch timing and disclosed program status where available.
- Capacity execution: Track commissioning, qualification, customer validation, commercial start, utilization, outages and capital spending. A capacity plan is not equivalent to production.
- Customer and program concentration: Assess reliance on a few customers, late-stage programs or products, as well as the extent of repeat business. Repeat wins can strengthen visibility without eliminating concentration risk.
- Economics: Compare growth with the relevant margin measure, pricing, foreign-exchange effects, capital needs, returns on new capacity and debt. A growth target alone says little about cash generation.
- Competitive alternatives: Consider customers’ in-house production and other providers. Outsourcing demand benefits an independent CDMO only when the work is actually awarded and economically attractive.
There is no independent sector-wide growth rate or sufficiently defined peer group in the company materials summarized here to support a defensible ranking of CDMOs. Company descriptions of “robust demand,” “secular tailwinds” or outperformance should be read as management characterizations, not independent market measurement.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
